Teva Company Profile
✉ Email this page to a colleague
What is the competitive landscape for TEVA, and when can generic versions of TEVA drugs launch?
TEVA has seven hundred and thirty-six approved drugs.
There are one hundred US patents protecting TEVA drugs. There are fifty-three tentative approvals on TEVA drugs.
There are nine hundred and thirteen patent family members on TEVA drugs in forty-nine countries and one thousand and fifty-three supplementary protection certificates in eighteen countries.
Summary for Teva
International Patents: | 913 |
US Patents: | 100 |
Tradenames: | 508 |
Ingredients: | 443 |
NDAs: | 736 |
Patent Litigation for Teva: | See patent lawsuits for Teva |
PTAB Cases with Teva as petitioner: | See PTAB cases with Teva as petitioner |
Drugs and US Patents for Teva
Expired US Patents for Teva
Paragraph IV (Patent) Challenges for TEVA drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Tablets | 0.5 mg and 1 mg | ➤ Subscribe | 2010-05-17 |
➤ Subscribe | Extended-release Capsule | 15 mg and 30 mg | ➤ Subscribe | 2008-08-11 |
➤ Subscribe | Injection | 40 mg/mL, 1 mL pre-filled syringe | ➤ Subscribe | 2014-01-29 |
➤ Subscribe | Tablets | 0.15 mg/0.03 mg | ➤ Subscribe | 2004-03-29 |
➤ Subscribe | Tablets | 0.15 mg/0.02 mg, 0.15 mg/0.025 mg, 0.15 mg/0.03 mg and 0.01 mg | ➤ Subscribe | 2013-07-10 |
➤ Subscribe | for Injection | 100 mcg/vial and 500 mcg/vial | ➤ Subscribe | 2015-04-14 |
➤ Subscribe | Tablets | 1 mg/0.02 mg and 75 mg | ➤ Subscribe | 2006-04-17 |
➤ Subscribe | Delayed-release Tablets | 20 mg | ➤ Subscribe | 2015-06-03 |
➤ Subscribe | Tablets | 5 mg, 10 mg, 20 mg, 30 mg | ➤ Subscribe | 2009-11-18 |
➤ Subscribe | Injection | 40 mg/mL, 1 mL pre-filled syringe | ➤ Subscribe | 2014-02-26 |
➤ Subscribe | Tablets | 0.15 mg/0.03 mg/0.01 mg | ➤ Subscribe | 2008-01-22 |
➤ Subscribe | Tablets | 0.1 mg/0.02 mg and 0.01 mg | ➤ Subscribe | 2009-11-16 |
➤ Subscribe | for Injection | 200 mcg/vial | ➤ Subscribe | 2015-05-01 |
➤ Subscribe | for Injection | 3.5 mg/vial | ➤ Subscribe | 2016-10-26 |
Premature patent expirations for TEVA
Expiration due to failure to pay maintenance fee
Patent Number | Expiration Date |
---|---|
⤷ Try a Trial | ⤷ Try a Trial |
International Patents for Teva Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Hong Kong | 1214990 | ⤷ Try a Trial |
European Patent Office | 2987523 | ⤷ Try a Trial |
South Korea | 20170122820 | ⤷ Try a Trial |
Spain | 2907984 | ⤷ Try a Trial |
Spain | 2860049 | ⤷ Try a Trial |
Japan | 2019059784 | ⤷ Try a Trial |
Japan | 2011524784 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Teva Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2498758 | 2090013-0 | Sweden | ⤷ Try a Trial | PRODUCT NAME: A COMBINATION OF METFORMIN HYDROCHLORIDE, SAXAGLIPTIN OR A PHARMACEUTICALLY ACCEPABLE SALT THEREOF, AND DAPAGLIFLOZIN OR PH ARMACEUTICALLY ACCEPTABLE SOLVATE THEREOF; REG. NO/DATE: EU/1/19/1401 20191113 |
0463756 | 99C0007 | Belgium | ⤷ Try a Trial | PRODUCT NAME: SILDENAFIL, NATL REGISTRATION NO/DATE: EU/1/98/077/001 19980914; FIRST REGISTRATION: CH 54642 19980622 |
0316704 | SPC/GB01/015 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: CAPECITABINE AND HYDRATES AND SOLVATES THEREOF; REGISTERED: CH 54657 19980610; UK EU/1/00/163/001-002 20010202 |
2635588 | C02635588/01 | Switzerland | ⤷ Try a Trial | PRODUCT NAME: VELPATASVIR + SOFOSBUVIR + VOXILAPREVIR; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 66510 08.12.2017 |
2962690 | C20190029 00295 | Estonia | ⤷ Try a Trial | PRODUCT NAME: APREMILAST;REG NO/DATE: EU/1/14/981 16.01.2015 |
1506211 | 122014000071 | Germany | ⤷ Try a Trial | PRODUCT NAME: KOMBINATION VON DAPAGLIFLOZIN ODER EINEM PHARMAZEUTISCH VERTRAEGLICHEN SALZ DAVON, UND METFORMIN ODER EINEM PHARMAZEUTISCH VERTRAEGLICHEN SALZ DAVON, GESCHUETZT DURCH DAS GRUNDPATENT EP 1 506 211; REGISTRATION NO/DATE: EU/1/13/900 20140116 |
0721777 | SPC/GB04/033 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: ATOMOXETINE, OPTIONALLY IN THE FORM OF A SALT, SUCH AS THE HYDROCHLORIDE; REGISTERED: UK PL 00006/0374 20040527; UK PL 00006/0375 20040527; UK PL 00006/0376 20040527; UK PL 00006/0377 20040527; UK PL 00006/0378 20040527; UK PL 00006/0379 20040527 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.